Zach Berman MD
@ZTBerman
Followers
274
Following
112
Media
39
Statuses
165
Meliorist and Monozukuri , #Bernedoodle Dad, Interventional Oncologist @UCSDHealth
San Diego, CA
Joined January 2012
**NEW IN JVIR:** Histopathologic Response and Oncologic Outcomes after Segmental and Subsegmental Transarterial Chemoembolization and Radioembolization for Hepatocellular Carcinoma ➡️ **Full Article:** https://t.co/6jPv1oOwxK
#InterventionalRadiology #IO #Y90 #MedEd
0
6
13
🔥Back-to-back days with publications. This one looking at dose models for predicting CPN with glass microspheres in HCC; voxel still best, higher MIRD not better at limit.🤔 It's TUMOR dose which matters.🔥 https://t.co/RHQKVYcnY4
@CVIR_Journal @ucsd_ir @bsc_io @BeauToskichMD
1
4
17
🔥Our most recent publication - this time a little different. A very unusual route of progression and metastasis after a patient received @histosonics Histotripsy for Cholangiocarcinoma.🔥 https://t.co/J0B89hVjgg Have others seen something like this?
jvir.org
As technologies emerge, it is important to be vigilant for new patterns of response. Histotripsy is a novel mechanical form of tumor disruption that has unknown long-term outcomes (1). This is an...
0
0
10
Always a fun time chatting with the BT team.
How can you make the decision to use pressure-enabled drug delivery? Whether it be Y90, TACE, or a neuroendocrine tumor, join expert @ZTBerman and host Dr. Christopher Beck as they discuss the design of these catheters and engage in a case based discussion. Tune in to add to
0
0
10
📣 All 6 episodes of Y90 Dosimetry University are now available to stream. Designed with physicians in mind, this series brings together expert perspectives and practical workflows for a comprehensive look at personalized Y90 dosimetry. 💻Free. On-demand. Peer-led. Now
0
3
9
This is huge. Congrats to @sio_central on showing what a society can do to push the field forward. Looking forward to the future of Interventional Oncology!
The @SIO_Central ACCLAIM Trial has officially reached its enrollment target. This study prospectively validates a reproducible technical endpoint in the treatment of colorectal liver metastases. Thank you, @bostonsci, NeuWave Medical, and @VarianMedSys. https://t.co/oiiC1nG3ly
0
0
5
How do experts balance aggressive tumor dosing with liver safety when treating HCC with Y90? Drs. Zach Berman & Tyler Sandow join Dr. Kavi Krishnasamy to break down real HCC cases, from large central tumors, portal vein invasion, and multifocal lesions. Tune in to glean insight
0
3
11
Glad to see our MultiD collaboration gaining traction. #PASTIME - @ucsd_ir @UCSD_ObGyn @rupalparikh90 @SIRspecialists
Placenta Accreta Spectrum (PAS) is a high-risk condition requiring coordinated care. This SIR MSC WIR infographic outlines the PASTIME approach as an IR model within a multidisciplinary framework #WIRSIR
0
0
3
🔥Our Recent Publication Highlighting the Importance of 💉Biopsy for HCC🔥 Even in the era of LI-RADS molecular profiling is/will be important for deciding 💊. https://t.co/TOzROALg4w
@ucsd_ir @UCSDRadRes @SIO_Central @_backtable @SIRspecialists @BeauToskichMD
0
1
6
Further confirmation of the high ORR and DoR of TARE for HCC. I suspect today marks the death of BSA and the beginning of the era of personalized dosimetry.
We're proud to announce that SIR-Spheres® is now the only FDA approved radioembolization therapy for both unresectable HCC & colorectal cancer liver metastases in the U.S. Read the full announcement: https://t.co/tNKhel6Bwd SIR-Spheres® Safety Info: https://t.co/WAB9e6Q3G9
0
2
7
Editor's Choice! 📖 Read this interesting commentary on the paper of Tahir et al, underlying the benefits of personalized dosimetry for radioembolization but also the limitations of the current methods. https://t.co/UsrlGgNY0J
0
3
9
In this discussion, the multidisciplinary panel focuses on a case of a non-cirrhotic patient with a solitary #HCC lesion that falls outside of ablation criteria. Stream the entire episode, with all case studies and imaging here: https://t.co/5GP2ciuljK Enroll in our free
0
2
3
Coming off of a great SIR, presenting our robotic ablation experience, here is a nice robotic MWA case for two obliquely placed probes covering an irregular CRC met with margin confirmation. @ucsd_ir @SIRspecialists @SIO_Central @QuantumSurgical @_backtable @_backtableONC
0
3
11
Is Y90 Dosimetry Adequately Taught During IR Fellowship?-- IRs reflect on their prior education in dosimetry and share their strategies for equipping trainees in this realm of practice Stream the full episode here: https://t.co/dn70d8ZXvR Enroll in our free BackTable+ course
0
5
20
Congratulations to our Best Traditional Poster and the Best Educational Exhibit presentation winners! Your research and work are amazing, and we're thrilled to recognize them at #SIR25NASH!
0
3
18
I am incredibly interested to see the results! Nice work NW team. Going to be a great session.
Preview one of SIR's Abstracts of the Year! Hear from @SamMouli on the Frontier Study: Preliminary Results of Safety and Feasibility of Yttrium-90 TheraSphere in Recurrent Glioblastoma. Read here: https://t.co/UtLTeTTEgb
#TheraSphereGBM #Y90 #FRONTIERstudy #SIR2025
0
0
7
Congrats to our new #radres! Welcome to @UCSDRadRes and @UCSDImaging!!! Thank you to our PD's and admins for your tireless efforts!
5
7
93
Congratulations to all on the match! We can't wait to meet our new UCSD IR and DR residents! #MatchDay2025
1
6
51
#Y90 radiation segmentectomy is now a recommended ablative modality by the AASLD for unresectable BCLC A #HCC or as a bridge to transplant. https://t.co/FJrCAJ9MN5 Post local therapy complete pathologic necrosis (CPN) of tumor has been associated with significantly improved post
0
22
65
Had a great time making this and learned a ton! Def recommend a listen.
A recent hepatocellular carcinoma (HCC) @_backtableONC episode tackles key cases, from multifocal HCC to post-transplant metastasis. Watch now with MCC's @ZTBerman & Dr. Adam Burgoyne: https://t.co/Rr8BCw7km9. 🎙️
0
2
7